CVRx, Inc.
CVRXCVRx, Inc. in brief
CVRx, Inc. is a listed company in the Medical Devices industry, based in Minneapolis, Minnesota, USA. Its market value was $48 M on 9 October 2026, which makes it the 21,428th largest listed company in the world and the 3,878th largest in the USA on this site. In the year to December 2025 it had sales of $57 M and a net loss of $53 M. It employs about 223 people and Kevin Hykes is its chief executive. By market, the largest shares of its 2025 sales came from USA (92%) and Germany (8%). Its shares trade under the symbol CVRX (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular disease. Barostim is the first medical technology approved by the U.S. Food and Drug Administration that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, which creates an imbalance in the brain’s Autonomic Nervous System resulting in excess neurohormones that drive HF progression. Barostim provides Baroreflex Activation Therapy, which links the cardiovascular system to the ANS. This therapy complements the pharmaceutical neurohormonal blockade, or Guideline Directed Medical Therapy, by increasing the signaling of the baroreceptors, thereby, reducing symptoms of HF. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in HF patients in the U.S. We estimate our total market opportunity using both prevalence and incidence epidemiologic models in which prevalence reflects the total number of individuals indicated for therapy at a given time, while incidence captures the annual occurrence of new cases meeting the indication. Based on these distinct models, we estimate that our prevalence-based market opportunity for HFrEF is $10.5 billion in the U.S. Using an incidence-based model, we estimate an annual market opportunity of $2.4 billion in the U.S.
From the company's annual report filed with the US SEC: read the report
CVRx, Inc. timeline
- 2003
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 1 July 2021; shares registered for exchange trading on 25 June 2021.
- 2025
- 💰Record revenue of $57 millionFY2025, the highest of the 6 years on record.
Events of CVRx, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,779 (Jan 2022) · #3,057 (Dec 2022) · #2,978 (Jul 2023) · #2,375 (Jan 2024) · #1,671 (Mar 2026) · #3,531 (Aug 2026) · #3,859 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.8×
- Price / book
- 1.2×
- Free cash flow yield
- -85.2%
- Net margin (TTM)
- -88.3%
- Operating margin
- -90.5%
- Return on equity
- -135.4%
- Liabilities / assets
- 62.5%
- Net debt
- $-26M
- Revenue growth
- +10.5%
- R&D / revenue
- 19.6%
- Revenue per employee
- $254 K
- Profit per employee
- $-239 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $57M | +10.5% | $-51M | $-53M | -94.1% |
| Dec 2024 | $51M | +30.5% | $-59M | $-60M | -116.9% |
| Dec 2023 | $39M | +74.9% | $-43M | $-41M | -104.8% |
| Dec 2022 | $22M | +72.3% | $-43M | $-41M | -184.4% |
| Dec 2021 | $13M | +115.5% | $-26M | $-43M | -330.4% |
| Dec 2020 | $6M | — | $-12M | $-14M | -233.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-40M | $1M | $-41M | $-2.04 | — |
| Dec 2024 | $-39M | $1M | $-41M | $-2.65 | — |
| Dec 2023 | $-39M | $1M | $-40M | $-1.99 | — |
| Dec 2022 | $-43M | $1M | $-43M | $-2.02 | — |
| Dec 2021 | $-28M | $1M | $-29M | $-4.16 | — |
| Dec 2020 | $-16M | $0M | $-16M | $-37.01 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $14M (-5.9% on a year earlier), net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations
- Sep 21, 20268-KCurrent reportDirectors or officers changed
- Aug 11, 20268-KCurrent reportDirectors or officers changed
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 9, 20268-KCurrent reportDirectors or officers changed
- Jun 3, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 11, 20268-KCurrent reportResults of operations
- Apr 20, 2026DEF 14AProxy statement
- Apr 13, 20268-KCurrent reportResults of operations · Other events
Official filings of CVRx, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $57 M
- Operating income
- $-51 M
- Net income
- $-53 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $105 M
- Total liabilities
- $65 M
- Total equity
- $39 M
As of December-2025
Top 87 institutional investors in CVRx, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 4,024,861 | 0 (0.00%) | 14.13% | $7 M | Oct 26, 2026 |
| 2 | NEA Management Company, LLC | 1,954,440 | 0 (0.00%) | 6.86% | $3 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 1,286,784 | +41,325 (+3.32%) | 4.52% | $2 M | Nov 13, 2026 |
| 4 | GSK plc | 1,007,583 | 0 (0.00%) | 3.54% | $2 M | Nov 5, 2026 |
| 5 | Vanguard Capital Management LLC | 902,426 | -8,150 (-0.90%) | 3.17% | $2 M | Nov 13, 2026 |
| 6 | Citadel Advisors LLC | 652,362 | +573,349 (+725.64%) | 2.29% | $1 M | Nov 16, 2026 |
| 7 | Royal Bank Of Canada | 516,789 | -716,423 (-58.09%) | 1.81% | $1 M | Nov 16, 2026 |
| 8 | Renaissance Technologies LLC | 435,400 | +205,400 (+89.30%) | 1.53% | $1 M | Nov 12, 2026 |
| 9 | Geode Capital Management, LLC | 423,090 | -17,696 (-4.01%) | 1.49% | $1 M | Nov 6, 2026 |
| 10 | Goldman Sachs Group Inc | 372,175 | +222,666 (+148.93%) | 1.31% | $1 M | Nov 16, 2026 |
| 11 | State Street Corp | 346,524 | -19,828 (-5.41%) | 1.22% | $1 M | Nov 12, 2026 |
| 12 | Morgan Stanley | 273,512 | +128,535 (+88.66%) | 0.96% | $0 M | Nov 13, 2026 |
| 13 | First Eagle Investment Management, LLC | 220,758 | New | 0.78% | $0 M | Nov 10, 2026 |
| 14 | Tudor Investment Corp Et Al | 208,058 | +2,374 (+1.15%) | 0.73% | $0 M | Nov 16, 2026 |
| 15 | D. E. Shaw & Co., Inc. | 200,756 | New | 0.70% | $0 M | Nov 16, 2026 |
| 16 | Accredited Investors Inc. | 200,000 | New | 0.70% | $0 M | Nov 3, 2026 |
| 17 | UBS Group AG | 189,925 | -34,308 (-15.30%) | 0.67% | $0 M | Nov 10, 2026 |
| 18 | Jacobs Levy Equity Management, Inc | 152,791 | New | 0.54% | $0 M | Nov 16, 2026 |
| 19 | Two Sigma Investments, LP | 131,935 | -463 (-0.35%) | 0.46% | $0 M | Nov 16, 2026 |
| 20 | Vanguard Fiduciary Trust Co | 128,685 | -270 (-0.21%) | 0.45% | $0 M | Nov 13, 2026 |
| 21 | Northern Trust Corp | 127,657 | +2,890 (+2.32%) | 0.45% | $0 M | Nov 16, 2026 |
| 22 | AQR Capital Management LLC | 120,637 | +15,023 (+14.22%) | 0.42% | $0 M | Nov 16, 2026 |
| 23 | Cresset Asset Management, LLC | 116,323 | +12,474 (+12.01%) | 0.41% | $0 M | Nov 16, 2026 |
| 24 | Vanguard Portfolio Management LLC | 107,921 | +2,006 (+1.89%) | 0.38% | $0 M | Nov 13, 2026 |
| 25 | Russell Investments Group, Ltd. | 100,937 | +96,426 (+2137.57%) | 0.35% | $0 M | Nov 6, 2026 |
All 87 institutional investors: 26 to 87, with who bought and sold →
Mutual funds holding CVRx, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 684,121 | $4 M | 4.3% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 371,607 | $2 M | 2.3% | <0.01% | −4.8% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 204,533 | $1 M | 1.3% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 165,915 | $1 M | 1.0% | <0.01% | +4.8% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 156,004 | $1 M | 0.98% | <0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 96,327 | $1 M | 0.61% | <0.01% | +0.8% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 81,934 | $0 M | 0.52% | <0.01% | +3.2% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 51,597 | $0 M | 0.33% | 0.02% | +29% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 34,330 | $0 M | 0.22% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 36,500 | $0 M | 0.23% | 0.13% | −26% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 35,398 | $0 M | 0.22% | <0.01% | +1.3% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 32,926 | $0 M | 0.21% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 27,837 | $0 M | 0.18% | <0.01% | +8.7% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 28,363 | $0 M | 0.18% | <0.01% | −32% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 27,822 | $0 M | 0.18% | 0.01% | +282% | Jul 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 27,216 | $0 M | 0.17% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 23,044 | $0 M | 0.15% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 22,120 | $0 M | 0.14% | <0.01% | +44% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 17,997 | $0 M | 0.11% | 0.03% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 15,982 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 16,021 | $0 M | 0.10% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 15,865 | $0 M | 0.10% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 14,695 | $0 M | 0.09% | <0.01% | −2.2% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 15,059 | $0 M | 0.10% | <0.01% | +70% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 14,568 | $0 M | 0.09% | <0.01% | +19% | Jun 30, 2026 |
As of Jul 31, 2026
Insider trading at CVRx, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | John LandryChief Financial Officer | Grant or award | +41,433 | — | — | 41,433 | Form 4 |
| filed | Brent BinkowskiCHIEF OPERATING OFFICER | Buy | +26,223 | $2.910 | $76 K | 56,514 | Form 4 |
| filed | Brent BinkowskiCHIEF OPERATING OFFICER | Sell10b5-1 plan | -1,309 | $2.550 | $3 K | 30,291 | Form 4 |
| filed | Joseph P. SlatteryDirector | Grant or award | +8,720 | — | — | 39,365 | Form 4 |
| filed | Michael D. DaleDirector | Grant or award | +29,005 | — | — | 29,005 | Form 4 |
| filed | Mitch C. HillDirector | Grant or award | +8,720 | — | — | 8,720 | Form 4 |
| filed | Kevin J. BallingerDirector | Grant or award | +8,720 | — | — | 8,720 | Form 4 |
| filed | Kirk G. NielsenDirector | Grant or award | +8,720 | — | — | 8,720 | Form 4 |
Markets and events: CVRx, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-40 reverse split
Trading halts
- 2026-11-06 14:36 UTC, code LUDP, resumed 14:41 UTC
- 2025-05-09 13:30 UTC, code LUDP, resumed 13:35 UTC
Fails to deliver
- : 2,012 shares at $1.68
- : 80 shares at $2.63
- : 513 shares at $2.88
- : 74 shares at $3.01
- : 3,885 shares at $3.04
CVRx, Inc. scorecard#
Passes 9 of the 22 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 9, 2026.
Valuation2 of 5
Growth4 of 6
Profitability1 of 5
Financial health2 of 5
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from CVRx, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -90.5% | -8.2% | |
| Net margin | -94.1% | -10.4% | |
| Return on equity | -96.6% | -16.8% | |
| Revenue growth, 3 years a year | 36.1% | 10.8% | |
| Revenue growth | 10.5% | 10.4% | |
| Debt to equity | 1.26× | 0.64× |
3of 9on the Piotroski tests of financial strength
- Net loss of $53 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$41 million.
- The share count rose 15.4% in the year.
- Revenue has grown 5 years in a row.
CVRx, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 57 | 51 | 39 | 22 | 13 | 6.1 | |
| Cost of revenue | 8.3 | 8.3 | 6.3 | 5.0 | 3.6 | 1.4 | |
| Gross profit | 48 | 43 | 33 | 17 | 9.4 | 4.6 | |
| Research and development | 11 | 11 | 12 | 10.0 | 7.5 | 6.4 | |
| Selling, general and administrative | 88 | 91 | 65 | 50 | 28 | 9.7 | |
| Operating expenses | 100 | 102 | 76 | 60 | 35 | 16 | |
| Operating income | −51 | −59 | −43 | −43 | −26 | −12 | |
| Interest expense and finance costs | 5.8 | 4.4 | 1.8 | 0.2 | 2.2 | 2.5 | |
| Other non-operating income (expense) | 3.8 | 4.0 | 3.9 | 1.4 | −15 | −0.0 | |
| Income before tax | −53 | −60 | −41 | −41 | −43 | −14 | |
| Income tax | −0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Net income including minority interests | −53 | −60 | −41 | −41 | −43 | −14 | |
| Net income attributable to shareholders | −53 | −60 | −41 | −41 | −43 | −14 | |
| Earnings per share, basic | -2.04 | -2.65 | -1.99 | -2.02 | -4.16 | -37.01 | |
| Earnings per share, diluted | -2.04 | -2.65 | -1.99 | -2.02 | -4.16 | -37.01 | |
| Shares, weighted average (basic) | 26 | 23 | 21 | 21 | 10 | — | |
| Shares, weighted average (diluted) | 26 | 23 | 21 | 21 | 10 | 0.4 | |
| Balance sheet | |||||||
| Cash and cash equivalents | 76 | 106 | 91 | 106 | 142 | 59 | |
| Receivables | 11 | 9.3 | 7.6r | 5.5 | 2.6 | 1.3 | |
| Inventory | 12 | 12 | 11 | 7.0 | 3.9 | 3.3 | |
| Other current assets | 3.1 | 2.5 | 3.0 | 4.2 | 2.6 | 0.6 | |
| Current assets | 102 | 130 | 112 | 123 | 151 | 64 | |
| Property, plant and equipment | 2.2 | 2.5 | 1.8 | 1.7 | 1.4 | 0.4 | |
| Right-of-use (leased) assets | 0.9 | 1.1 | 1.3 | 0.3 | 0 | — | |
| Total assets | 105 | 133 | 115 | 125 | 153 | 65 | |
| Accounts payable | 3.8 | 2.6 | 1.9 | 1.7 | 0.5 | 0.5 | |
| Debt due within a year | — | — | — | — | — | 0 | |
| Current liabilities | 13 | 11 | 7.9 | 8.1 | 5.9 | 8.0 | |
| Long-term debt | 50 | 49 | 29 | 6.7 | 0 | 19 | |
| Lease liabilities (non-current) | 0.6 | 0.9 | 1.2 | 0.1 | 0 | — | |
| Total liabilities | 65 | 62 | 39 | 16 | 6.6 | 28 | |
| Retained earnings | −591 | −537 | −477 | −436 | −395 | −352 | |
| Shareholders' equity | 39 | 71 | 76 | 109 | 146 | −293 | |
| Total liabilities and equity | 105 | 133 | 115 | 125 | 153 | 65 | |
| Shares outstanding | 26 | 25 | 21 | 21r | 20 | 0.4 | |
| Cash-flow statement | |||||||
| Share-based compensation | 11 | 19 | 6.3 | 3.9 | 1.9 | 0.1 | |
| Cash from operating activities | −40 | −39 | −39 | −43 | −28 | −16 | |
| Capital expenditure | −0.6 | −1.4 | −0.6 | −0.7 | −1.2 | −0.3 | |
| Cash from investing activities | −0.6 | −1.4 | −0.6 | −0.7 | −1.2 | −0.3 | |
| Debt repaid | — | — | — | 0 | −21 | 0 | |
| Shares issued | 9.0 | 33 | 0 | 0 | 133 | 0 | |
| Cash from financing activities | 11 | 56 | 24 | 7.5 | 112 | 50 | |
| Exchange-rate effect on cash | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | |
| Change in cash | −30 | 15 | −16 | −36 | 83 | 33 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2026
What CVRx, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Countries and regions
- 🇺🇸 USA$52 M92%+10.0%
- 🇩🇪 Germany$5 M8.4%+16%
As of Dec 31, 2025
Where CVRx, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | $52 M92% |
| 🇩🇪 Germany | $5 M8.4% |
Events at CVRx, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 7 · Material agreement 2 · New debt 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 15
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtResults announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| New debt | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officersResults announced | 8-K |
As of Nov 5, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
H-1B hiring at CVRx, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $101 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Clinical Research Associate IIClinical Research Coordinators | 1 | $101 K |
Where: Minneapolis, MN 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $101 K | 1 |
| FY2024 | 1 | 1 | $70 K | 1 |
How CVRx, Inc. compares in Medical Devices
- Market cap$48 M · higher than 26% of 142
- Revenue$57 M · higher than 30% of 156
- Net margin-88.3% · higher than 17% of 145
- Revenue growth10.4% · higher than 50% of 105
- Price / sales0.8× · lower than 91% of 96
- Price / book1.2× · lower than 82% of 99
- FCF yield-85.2% · higher than 5% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CVRx, Inc.🇺🇸 | $48 M | — | -88.3% | +10.4% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
How current the figures are
- Market cap:
- Oct 9, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CVRx, Inc.? Verify and update this profile — free
Show CVRx, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.